Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 vs TPC in Recurrent or Metastatic Cervical Cancer
NCT06459180Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in Cervical Cancer (CC), sponsored by Merck & Co.. Started Jul 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06459180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06459180.